Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

The sNDA for empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure and slow kidney function decline in adults with chronic heart failure with ...

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

Results for EMPEROR-Reduced have been highly anticipated, as they are expected to set off a new round of competition in the drug class, which was first developed to treat type 2 diabetes.

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet RAHWAY, N.J., ...

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...

The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

It is important that all adults with chronic heart failure with reduced ejection fraction are given all appropriate medications at an optimal tolerated dose to best manage their condition and provide ...